Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Upcoming changes to precertification requirements for 2016

December 1, 2015

As a reminder, in 2016 new precertification requirements will apply to our commercial and Medicare Advantage HMO and PPO members for the following service and drugs.

Service

Bronchial thermoplasty will require precertification approval from Independence in 2016 as follows:

  • Effective January 1, 2016, precertification will be required for members enrolled in Medicare Advantage plans.
  • Effective March 1, 2016, precertification will be required for members enrolled in commercial plans.

Drugs

As of January 1, 2016, the seven medical benefit drugs listed below will require precertification approval from Independence:

  • Adagen® (pegademase bovine)
  • Blincyto® (blinatumomab)
  • Cyramza® (ramucirumab)
  • Imlygic (talimogene laherparepvec)
  • Kanuma (sebelipase alfa)*
  • Lemtrada® (alemtuzumab)
  • Nucala® (mepolizumab)

These changes will be reflected in updated precertification requirement lists, which will be posted later this month on our website.

In addition, Notifications for the medical policies for Adagen (pegademase bovine) and Cyramza (ramucirumab) will be available this month:

  • Adagen (pegademase bovine):
    • Commercial: #08.01.26: Pegademase bovine (Adagen®)
  • Cyramza (ramucirumab):
    • Commercial: #08.01.25: Ramucirumab (Cyramza®)
    • Medicare Advantage: #MA08.075: Ramucirumab (Cyramza®)

To view the Notifications for these policies, visit our Medical Policy Portal. Select Accept and Go to Medical Policy Online, and then select Commercial or Medicare Advantage under Notifications.

In January 2016, new policies for Imlygic (talimogene laherparepvec) and Nucala® (mepolizumab) will be made available. Medical necessity criteria for these drugs will be based on the U.S. Food and Drug Administration (FDA)-approved indications.

*Pending approval from the FDA


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.